Palisade Bio Stock Performance

PALI Stock  USD 1.49  0.12  7.45%   
The company holds a Beta of 1.23, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Palisade Bio will likely underperform. Palisade Bio right now holds a risk of 7.14%. Please check Palisade Bio treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Palisade Bio will be following its historical price patterns.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Palisade Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong essential indicators, Palisade Bio is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Last Split Factor
1:15
Dividend Date
2019-07-18
Last Split Date
2024-04-08
1
Palisade Bio Approves Key Proposals at Stockholder Meeting - TipRanks
12/04/2025
2
Palisade Bio Stock Surge Whats Behind the Rise - StocksToTrade
12/10/2025
3
Palisade Bio Upgraded to Buy Heres What You Should Know
12/19/2025
4
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
12/30/2025
5
Palisade Bio soars 5 percent ahead of clinical trial results - MSN
01/06/2026
6
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com
01/08/2026
7
Palisade Bio director Williams buys 9,400 in shares - Investing.com
01/13/2026
8
Acquisition by Williams Donald Allen of 5000 shares of Palisade Bio at 1.6712 subject to Rule 16b-3
01/16/2026
9
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
01/29/2026

Palisade Bio Relative Risk vs. Return Landscape

If you would invest  168.00  in Palisade Bio on November 5, 2025 and sell it today you would lose (19.00) from holding Palisade Bio or give up 11.31% of portfolio value over 90 days. Palisade Bio is currently generating 0.0495% in daily expected returns and assumes 7.1386% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Palisade, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Palisade Bio is expected to generate 1.52 times less return on investment than the market. In addition to that, the company is 9.41 times more volatile than its market benchmark. It trades about 0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.1 per unit of volatility.

Palisade Bio Target Price Odds to finish over Current Price

The tendency of Palisade Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.49 90 days 1.49 
about 98.0
Based on a normal probability distribution, the odds of Palisade Bio to move above the current price in 90 days from now is about 98.0 (This Palisade Bio probability density function shows the probability of Palisade Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.23 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Palisade Bio will likely underperform. Additionally Palisade Bio has an alpha of 0.0421, implying that it can generate a 0.0421 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Palisade Bio Price Density   
       Price  

Predictive Modules for Palisade Bio

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Palisade Bio. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.071.478.64
Details
Intrinsic
Valuation
LowRealHigh
0.224.4611.63
Details
Naive
Forecast
LowNextHigh
0.031.558.72
Details
3 Analysts
Consensus
LowTargetHigh
12.1913.4014.87
Details

Palisade Bio Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Palisade Bio is not an exception. The market had few large corrections towards the Palisade Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Palisade Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Palisade Bio within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.04
β
Beta against Dow Jones1.23
σ
Overall volatility
0.22
Ir
Information ratio 0.01

Palisade Bio Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Palisade Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Palisade Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Palisade Bio had very high historical volatility over the last 90 days
Palisade Bio may become a speculative penny stock
Palisade Bio has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (14.44 M) with profit before overhead, payroll, taxes, and interest of 0.
Palisade Bio currently holds about 5 M in cash with (12.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Palisade Bio has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Palisade Bio Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Palisade Stock often depends not only on the future outlook of the current and potential Palisade Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Palisade Bio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding1.4 M
Cash And Short Term Investments9.8 M

Palisade Bio Fundamentals Growth

Palisade Stock prices reflect investors' perceptions of the future prospects and financial health of Palisade Bio, and Palisade Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Palisade Stock performance.

About Palisade Bio Performance

By evaluating Palisade Bio's fundamental ratios, stakeholders can gain valuable insights into Palisade Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Palisade Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Palisade Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.19)(1.25)
Return On Capital Employed(1.75)(1.84)
Return On Assets(1.19)(1.25)
Return On Equity(2.22)(2.33)

Things to note about Palisade Bio performance evaluation

Checking the ongoing alerts about Palisade Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Palisade Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Palisade Bio had very high historical volatility over the last 90 days
Palisade Bio may become a speculative penny stock
Palisade Bio has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (14.44 M) with profit before overhead, payroll, taxes, and interest of 0.
Palisade Bio currently holds about 5 M in cash with (12.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Palisade Bio has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
Evaluating Palisade Bio's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Palisade Bio's stock performance include:
  • Analyzing Palisade Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Palisade Bio's stock is overvalued or undervalued compared to its peers.
  • Examining Palisade Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Palisade Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Palisade Bio's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Palisade Bio's stock. These opinions can provide insight into Palisade Bio's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Palisade Bio's stock performance is not an exact science, and many factors can impact Palisade Bio's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Palisade Stock analysis

When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities